Targeting the lipid envelope to control COVID-19
Viruses can be grouped into enveloped or nonenveloped. When enveloped viruses are shed by the host cell, they take part of the cell’s membrane and use it to surround themselves with a lipid envelope. Enveloped viruses include SARS-CoV-2, influenza and HIV. However, little research has been done on viral envelopes’ composition or how they could be used to target the virus directly.

disturb the lipid envelope of the SARS-CoV-2 molecule and affect the presence
of the virus in patients.
Early in the COVID-19 pandemic, governments around the world told people to wash their hands with soap and water for at least 20 seconds or use hand sanitizer with at least 60% ethanol to minimize the virus’ spread; the idea was to dissolve the envelope. Valerie O’Donnell, a lipid biochemist and professor at Cardiff University, saw all this and asked one question: If soap can inactivate virus on our hands, could it do this in our throat?
“SARS-CoV-2 is being shed from the back of the throat, but no one is thinking about lipid membranes,” she said. When she began her research, “All the focus (was) on vaccines.”
In a recent , O’Donnell and a multidisciplinary team describe how they determined SARS-CoV-2’s lipid envelope composition and began testing how to use this information to target virus envelope degradation with existing commercial products, such as oral rinses.
If the virus has a membrane similar to a cell, SARS-CoV-2 should be sensitive to detergents; by targeting the envelope, the researchers could target the virus itself. The team first focused on the composition of the envelope to answer the question, Is the virus’ membrane similar to a cell membrane?
O’Donnell’s team found that the SARS-CoV-2 virus envelope consists mainly of phospholipids with some cholesterol and sphingolipids. Compared with cellular membranes, the SARS-CoV-2 envelope has higher levels of aminophospholipids on the outer surface. Exposed aminophospholipids are known to promote a pro-inflammatory environment, which might contribute to inflammation-related problems in COVID-19.
The composition of the SARS-CoV-2 envelope is such that it should be disrupted easily using soaps (surfactants). O’Donnell next proposed testing this by teaming up with dentists and virologists to determine if any oral rinse or mouthwash on the market could target and destroy these virus envelopes.
In collaboration with Richard Stanton and David Thomas at Cardiff University, the researchers tested various mouthwashes on patients hospitalized with COVID-19. They found that mouthwashes containing the antiseptic cetylpyridinium chloride eliminated the virus for at least one hour in about half the patients tested, whereas povidone-iodine and saline mouthwashes had little or no effect.
In the future, the team plans to study how the inflammatory mechanisms of the cells might affect the composition of the viral lipid envelope.
“Vaccines are not a complete solution,” O’Donnell said.
Preventive measures that target the virus in the throat or nasal passages have potential to combat COVID-19 transmission. Understanding the composition of SARS-CoV-2 lipid envelope membranes might provide new ways to target the virus and further elucidate how the virus interacts with host cells.
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.